Business Context and Reporting Period
Company: Revelation Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 15, 2022
Reporting Period Covered: Three and six months ended June 30, 2022
This filing serves as a notification that the Company issued a press release on August 15, 2022, announcing financial results for the period ended June 30, 2022, and providing program updates. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes regarding financial performance or operations are detailed within the text of this specific filing. The document indicates that such information is contained in the referenced press release.
Guidance, Outlook, and Risks
Management Commentary: The Company issued program updates alongside the financial results announcement.
Legal Disclaimer: The information in Item 2.02, Item 7.01, and Exhibit 99.1 is not treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 15, 2022) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "program updates" mentioned in Item 7.01.
- Confirm the status of the Company's securities (Units REVBU, Common Stock REVB, Warrants REVBW) on the NASDAQ Stock Market.
- Note that the Company is classified as an emerging growth company.